Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Glazer

Showing results (11-20 of 535) with videos related to

Pageof 54
Sort By:
The Journal of Clinical Psychiatry|December 10, 1998
Formulary decisions and health economicsW M Glazer
The Journal of Clinical Psychiatry|May 1, 1984
Depot fluphenazine: risk/benefit ratioW M Glazer
Schizophrenia Research|November 1, 1988
Fluphenazine decanoate. Its steady-state pharmacologic profile and relationship to tardive dyskinesiaW M Glazer
Current Molecular Medicine|March 20, 2002
Directed gene modification via triple helix formationL Gorman, P M Glazer
The Journal of Clinical Investigation|May 12, 2015
Tumor suppressor p53 stole the AKT in hypoxiaZhong Yun, Peter M Glazer
Schizophrenia Research|October 1, 1990
A comparison of masking effects of haloperidol versus molindone in tardive dyskinesiaW M Glazer, H Hafez
The Journal of Clinical Psychiatry|August 1, 1996
A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patientsW M Glazer, L Ereshefsky
Proceedings of the National Academy of Sciences of the United States of America|April 8, 2004
Cell-interdependent cisplatin killing by Ku/DNA-dependent protein kinase signaling transduced through gap junctionsRyan Jensen, Peter M Glazer
Mutation Research|August 1, 1998
Mutagenesis induced by the tumor microenvironmentJ Yuan, P M Glazer
Archives of General Psychiatry|September 1, 1993
Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia StudyH Morgenstern, W M Glazer
Pageof 54

Showing results (11-20 of 535) with videos related to

Sort By:
Pageof 54
The Journal of Clinical Psychiatry|December 10, 1998
Formulary decisions and health economicsW M Glazer
The Journal of Clinical Psychiatry|May 1, 1984
Depot fluphenazine: risk/benefit ratioW M Glazer
Schizophrenia Research|November 1, 1988
Fluphenazine decanoate. Its steady-state pharmacologic profile and relationship to tardive dyskinesiaW M Glazer
Current Molecular Medicine|March 20, 2002
Directed gene modification via triple helix formationL Gorman, P M Glazer
The Journal of Clinical Investigation|May 12, 2015
Tumor suppressor p53 stole the AKT in hypoxiaZhong Yun, Peter M Glazer
Schizophrenia Research|October 1, 1990
A comparison of masking effects of haloperidol versus molindone in tardive dyskinesiaW M Glazer, H Hafez
The Journal of Clinical Psychiatry|August 1, 1996
A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patientsW M Glazer, L Ereshefsky
Proceedings of the National Academy of Sciences of the United States of America|April 8, 2004
Cell-interdependent cisplatin killing by Ku/DNA-dependent protein kinase signaling transduced through gap junctionsRyan Jensen, Peter M Glazer
Mutation Research|August 1, 1998
Mutagenesis induced by the tumor microenvironmentJ Yuan, P M Glazer
Archives of General Psychiatry|September 1, 1993
Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia StudyH Morgenstern, W M Glazer
Pageof 54